What explains the diffusion of treatments for mental illness? - Wikidata - awgldk - TriplyDB

What explains the diffusion of treatments for mental illness?

What explains the diffusion of treatments for mental illness?

http://www.wikidata.org/entity/Q37108584

about

Improving quality and diffusing best practices: the case of schizophrenia.Does managed care affect the diffusion of psychotropic medications?Barriers to use of pharmacotherapy for addiction disorders and how to overcome them.Where You Live Matters: Quality and Racial/Ethnic Disparities in Schizophrenia Care in Four State Medicaid Programs.The effect of race-ethnicity and geography on adoption of innovations in the treatment of schizophrenia.Ten-year trends in quality of care and spending for depression: 1996 through 2005.Barriers and Facilitators to Sustainment of an Evidence-Based Supported Employment Program.Patterns of Antipsychotic Prescribing by Physicians to Young Children.Trends in the use and cost of antipsychotics among older adults from 2007 to 2013: a repeated cross-sectional study.New directions for psychiatric rehabilitation in the USA.Does mental health staffing level affect antipsychotic prescribing? Analysis of Italian national statistics.

P2860

Q33704267-DB38C9B4-F075-4112-9590-75C43735273A Q35112617-5C2C5E19-4840-44D9-A007-4D34EBDC75A1 Q35490468-22EF3BFE-5DD0-4626-8E2B-C97789BB7259 Q36144487-3275A38C-903A-4BFF-B7BC-A44A687B2540 Q36884944-5C424547-A4FD-4B5B-870C-AA80735BDC85 Q36924338-495ACA03-FD63-49D5-A9B0-4422AE1873BD Q39149784-82B501C9-9909-4B4B-8F65-6A4BAF009D08 Q39600765-A3A1E229-B955-4B95-8387-24A8D2AC398F Q39615684-9EF5C06F-5DEB-4947-89A6-5A04DD3BBC18 Q47873102-D6E73DF5-B760-4B11-BBE0-08E9842759B9 Q54968788-76930A3A-A840-4818-8239-B7778828C4BA

P2860

What explains the diffusion of treatments for mental illness?

http://www.wikidata.org/entity/Q37108584

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

What explains the diffusion of treatments for mental illness?

@en

What explains the diffusion of treatments for mental illness?

@nl

type

label

What explains the diffusion of treatments for mental illness?

@en

What explains the diffusion of treatments for mental illness?

@nl

prefLabel

What explains the diffusion of treatments for mental illness?

@en

What explains the diffusion of treatments for mental illness?

@nl

P1433

Q37108584-ADD0B809-8656-4A32-AC53-01511DF0B0A6

P1476

Q37108584-0B1BCCF1-E1B2-4680-903A-C906BE57A760

P2093

Q37108584-987CFC89-B64D-40E7-A5A7-7647A5144250

Q37108584-DE251D1B-C935-49C0-80DF-AA50725A77D6

P2860

Q37108584-0EF6E76A-707B-4223-92E9-9A0788375087

Q37108584-11693E92-2D8A-4AF2-83D0-2DAA3D6568A4

Q37108584-1CE29573-A330-4E19-AE65-5E8FFFBC9351

Q37108584-3205B89A-1DAF-481F-9495-EC405D4E7E25

Q37108584-34BF33AD-9763-4FAB-B530-D58AC3B7C4ED

Q37108584-407C4FFA-B6A4-41FB-9013-1316E66E88C3

Q37108584-423578E1-401D-4A7C-91E1-F5C5296FCCCA

Q37108584-57F7C844-4072-43CB-916C-E308C7C64A75

Q37108584-5AB674EB-D608-4FFF-B19C-781DB9F152F7

Q37108584-657CF50D-5F97-495A-94A7-BE8ED29C0EA0

P304

Q37108584-03991384-CAF8-4704-AA8F-579193BBBBBE

P31

Q37108584-5A8304B9-EA9F-464E-B1A7-2E0C8D14534A

P356

Q37108584-34A5DD3D-073E-4896-8BB2-2F3641F28B99

P407

Q37108584-F64563E8-D2D6-4487-9B5D-6AF4162C7243

P433

Q37108584-3FC3ACFC-BCEC-4B06-AC42-C338BC03DB69

P478

Q37108584-DD1AFEA7-FD27-4733-9892-AF49BE597D86

P50

Q37108584-D38BE70F-34CD-4534-8D73-469EDEF248D9

P577

Q37108584-087BDE11-F93E-4031-9FF9-0254883CA3E4

P5875

Q37108584-BC403433-4D88-41D0-8643-8AA2313ABB91

P698

Q37108584-E5A8C492-D164-4C11-B23A-B409AF618188

P932

Q37108584-E18175FC-3FEE-474C-B4E5-DEC949121C7D

P356

APPI.AJP.2008.08030334

P1433

American Journal of Psychiatry

P1476

What explains the diffusion of treatments for mental illness?

@en

P2093

Howard H Goldman

http://www.w3.org/2001/XMLSchema#string

Jonathan Skinner

http://www.w3.org/2001/XMLSchema#string

P2860

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

Diffusion of innovations in service organizations: systematic review and recommendations

Barriers to the use of medications to treat alcoholism.

Medical care costs: how much welfare loss?

Psychiatric practice variations in the diagnosis and treatment of major depression.

Disseminating innovations in health care.

Physical health monitoring of patients with schizophrenia.

A meta-analysis of the efficacy of second-generation antipsychotics.

Beta blockade during and after myocardial infarction: an overview of the randomized trials.

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

P304

1385-1392

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1176/APPI.AJP.2008.08030334

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

165

http://www.w3.org/2001/XMLSchema#string

P50

Robert E. Drake

P577

2008-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23448443

http://www.w3.org/2001/XMLSchema#string

P698

18981070

http://www.w3.org/2001/XMLSchema#string

P932

2647364

http://www.w3.org/2001/XMLSchema#string